Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114016 | 0.87 | HTR4 (0.35) | CYP4F2CYP4A11 | |
| SCHEMBL1970718 | 0.87 | CYP4F2 (0.40) | CYP4F2CYP4A11NPSR1MAPTKDM1A | |
| SCHEMBL1968493 | 0.84 | CYP4F2 (0.37) | CYP4F2CYP4A11KDM1ASMN1; SMN2 | |
| SCHEMBL1971371 | 0.79 | DRD2 (0.43) | SMN1; SMN2EPHX1 | |
| SCHEMBL2989855 | 0.78 | DRD2 (0.43) | SMN1; SMN2EPHX1 | |
| SCHEMBL24577446 | 0.77 | CYP4F2 (0.46) | CYP4F2CYP4A11NPSR1KDM1ASMN1; SMN2 | |
| SCHEMBL1973738 | 0.76 | DRD2 (0.43) | SMN1; SMN2EPHX1 | |
| SCHEMBL5114260 | 0.75 | HTR4 (0.34) | MAPTSMN1; SMN2 | |
| SCHEMBL31733064 | 0.74 | CYP4F2 (0.37) | CYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL31733093 | 0.74 | CYP4F2 (0.37) | CYP4F2CYP4A11SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8816090-B2 | Benzisoxazole derivatives | PFIZER INC. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-1856114-B1 | BENZISOXAZOLE DERIVATIVES | PFIZER (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20080207690-A1 | Benzisoxazole Derivatives | RAQUALIA PHARMA INC. (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1856114-A1 | BENZISOXAZOLE DERIVATIVES | Pfizer, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006090224-A1 | BENZISOXAZOLE DERIVATIVES | PFIZER JAPAN INC. (JP) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207690-A1 | Benzisoxazole Derivatives | BRS3, MRGPRX4, HTR4 | CYP4F2 681/4885CYP4A11 451/4885NPSR1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.